Day One - ET (Eastern Time, GMT-05:00)
Day One - ET (Eastern Time, GMT-05:00)
Solution Summit: Anaplan vs Excel: What Should Your GTN Forecasting Solution Look Like?
Join us for a hands-on demonstration where we highlight key differences between solution platforms. If you’ve been wondering what can be accomplished using Excel versus an EPM platform like Anaplan, you won’t want to miss this! We’ll reveal the power, flexibility, and scalability of the EPM route, while also making clear what’s achievable within Excel. Questions to consider:
- How can I achieve multiple forecasting methodologies and the flexibility to apply the best fit by forecast period?
- What does a real-time GP calculation look like inside my GTN Forecasting model?
- How can comprehensive price protection modeling take shape depending on the technology I choose?
- How do I adjust my model to accommodate market and regulatory changes without having to wait on solution vendors?
For each of these questions and more, we won’t just tell you the answer — we’ll show you what things look like inside a best-practice Excel model versus our Anaplan GTN Forecasting prototype. We look forward to seeing you!
- Michael McCarthy - Partner, Pharosity Consulting
- Brian Barbash - Partner, Pharosity Consulting
- William Murray Brown - Senior Solution Architect, Twelve Consulting Group
- John Ly - Principal Consultant, Pharosity Consulting
- Prakash Chainani - Vice President – Finance, HR & IT, Lifestar Pharma LLC (a Mankind Group Company)
- Explore the latest developments for the IRA, CMS and AMP cap removal and its implications
- Top tips and pitfalls to avoid when ensuring regulatory financial compliance and planning
- Mapping the political and legislative landscape and what’s on the horizon
- Jeff Baab - Vice President, Operational Consulting, IntegriChain
- Anthony Fiordaliso - Vice President, US Commercial Contracts & Pricing, AbbVie
- Sean Dickson - Senior Vice President, Pharmaceutical Policy and Strategy, America's Health Insurance Plans
- Chris Sloan - Director, Market Access Strategy, Blueprint Medicines
- Chris Schott - Partner, Latham & Watkins
- Assessing the company’s GTN needs - use of automation, cloud & software in supporting GTN
- In-house vs. outsourced solutions
- What impact will AI have on analytics and forecasting?
- Ensuring you have capable processes, cross functional collaboration and talent in place to support technology implementation
- Jennifer Sharpe - Vice President, Gross-to-Net Consulting and Facilitator, Revenue Analytics Collaborative, IntegriChain
- Rochelle Cupelli - VP, Finance, Ironshore Pharmaceuticals
- Frank Panaro - Director, Corporate Finance, Sunovion Pharmaceuticals
- Melissa Norton - Assistant Controller, Revenue, Tolmar
- Ekaterina Miteiko - Associate Director, Financial Planning & Analytics, Operations & Strategy, Mitsubishi Tanabe Pharma America, Inc.
- George Kappus - Associate Director, M&S Controlling (GtN), Boehringer Ingelheim USA Corporation
- Kary Callahan - Director, Finance, Paratek Pharmaceuticals
- Fern Paul-Aviles - Assistant Vice President, 340B, Pharmacy Population Health Strategy, and Non-acute Pharmacy service lines, Atrium Health
- Jeff Baab - Vice President, Operational Consulting, IntegriChain
- Harnessing technological innovation & tools for enhancing forecasting & analytical capabilities
- Improving skills through talent management, training and retaining knowledge
- Futureproofing your organization and succession planning
- Tom Evegan - Principal, Life Sciences Consulting Leader, RSM US LLP
- Matt Green - Senior Director, Financial Planning & Analysis, Ferring Pharmaceuticals Inc.
- Daya Harvey - Senior Director, Ops Finance FP&A CoE Lead, CSL Behring
- Robert Ruitenberg - Senior Director, Forecasting, Teva Pharmaceuticals
- Meera Phaltankar - Director of Revenue Accounting, Ironshore Pharmaceuticals, Inc.
- Lan Zhou - Director of FP&A, Ikena Oncology
- Prakash Chainani - Vice President – Finance, HR & IT, Lifestar Pharma LLC (a Mankind Group Company)
- Brett Nussbaum - Director of Gross to Net Accounting, Novartis
- Partha Chatterjee - Partner, Akara Group LLC
- Romit Kamdar - Partner, Akara Group LLC
Branded specialty products go through varying phases of Gross-to-Net based off contracting decisions, market events, and life cycle management decisions. This session will share examples of the Gross-to-Net evolution from Launch to LOE and how each decision made can impact a brands P&L.
- Dan Sacchetta - Director Managed Markets Finance- Gross-to-Net, Novartis
- Timothy Bonn - Senior Director, Gross to Net, Breakaway Technologies
- Patrick Coyle - Former Vice President & CFO, Eisai Inc.
- Key considerations for pharma, biotechs and generics when it comes to GTN optimization
- Forecasting the branded prescription drug fee within GTN
- Evaluating whether generics manufacturers should outsource activities or invest in automation
- Patrick Coyle - Former Vice President & CFO, Eisai Inc.
- Jeffrey Miller - Assistant Vice President and Corporate Controller, Lannett Company
- Jennifer Winterhalter - Vice President, Revenue Management, Amneal Pharmaceuticals
- Sandra Miceli - Finance Executive / Consultant, Cormedix
- Frank Panaro - Director, Corporate Finance, Sunovion Pharmaceuticals
- Walter Worsham - Managing Director, Federal Compliance Solutions LLC
- Improve data circulation through automation, unified roster management and pre-screen chargeback disputes
- Ingest quality information to for a higher performing GTN forecast and to support future negotiations
- Heal your (technology and process) environment by reducing intermediary systems and unifying on sources of truth for data and forecasts
- Walter Worsham - Managing Director, Federal Compliance Solutions LLC
- Kaushal Kishore - Head Strategy Pricing and Data Science, Merck KGaA
- Ekaterina Miteiko - Associate Director, Financial Planning & Analytics, Operations & Strategy, Mitsubishi Tanabe Pharma America, Inc.
- Kary Callahan - Director, Finance, Paratek Pharmaceuticals